A Real-World Study to Investigate the Efficacy and Safety of Aprepitant Injection in Preventing Chemotherapy-Induced Nausea and Vomiting

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300069353

Enrollment

Unknown

Registered

2023-03-14

Start date

2023-03-15

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of chemotherapy-related nausea and vomiting

Interventions

Patients who have received prophylactic antiemetic therapy with Arepitan:NA

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who have been treated with Aprepitant for preventive antiemesis in clinical practice.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
The proportion of subjects with complete response (no vomiting and no remedial therapy) during treatment (0-120 hours);	—

Secondary

Measure	Time frame
The proportion of subjects with complete response in acute phase (0-24 hours) and delayed phase (24-120 hours);The proportion of subjects with complete control (no vomiting, no remedial therapy and no mild nausea (VAS < 25mm)) during treatment;The proportion of patients with different grades of nausea/vomiting in different periods;The proportion of subjects receiving remedial therapy;Time to treatment failure (according to the time of first vomiting attack or remedial therapy, whichever occurs first);Changes of FLIE score before and after treatment;Changes of Hospital Anxiety and Depression Scale (HAD) score before and after treatment;	—

Measure

Time frame

The proportion of subjects with complete response in acute phase (0-24 hours) and delayed phase (24-120 hours);The proportion of subjects with complete control (no vomiting, no remedial therapy and no mild nausea (VAS < 25mm)) during treatment;The proportion of patients with different grades of nausea/vomiting in different periods;The proportion of subjects receiving remedial therapy;Time to treatment failure (according to the time of first vomiting attack or remedial therapy, whichever occurs first);Changes of FLIE score before and after treatment;Changes of Hospital Anxiety and Depression Scale (HAD) score before and after treatment;

—

Countries

China

Contacts

Public ContactSuxia Luo

Henan Cancer Hospital

luosxrm@163.com+86 186 3855 3211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026